Related Experiment Video
Updated: Feb 11, 2026

09:45
An In Vitro Protocol for Evaluating MicroRNA Levels, Functions, and Associated Target Genes in Tumor Cells
Published on: May 21, 2019
8.9K
MicroRNA 199a-5p induces apoptosis by targeting JunB
Mengjie Yan1, Sibao Yang1, Fanbo Meng1
1Department of Internal Medicine and Cardiology, China-Japan Union Hospital of Jilin University, Changchun, 130033, China.
Scientific Reports
|April 29, 2018
Summary
MicroRNA miR-199a-5p levels rise with heart failure (HF) progression. This microRNA promotes cardiomyocyte apoptosis by targeting the JunB gene, indicating its role in heart damage.
Area of Science:
- Cardiovascular Biology
- Molecular Cardiology
- MicroRNA Research
Background:
- MicroRNAs (miRNAs) are key regulators in cardiac physiology and pathology.
- Previous studies indicated elevated miR-199a-5p in failing hearts, but its specific role remained unknown.
- Heart failure (HF) involves complex molecular mechanisms, including cardiomyocyte apoptosis.
Purpose of the Study:
- To investigate the role of miR-199a-5p in the progression of heart failure (HF).
- To determine if miR-199a-5p mediates cardiomyocyte apoptosis.
- To identify molecular targets of miR-199a-5p in the context of HF.
Main Methods:
- Utilized a rat model of acute myocardial infarction to induce heart failure.
- Employed biochemical and molecular biology techniques to quantify miR-199a-5p levels.
- Performed cell culture experiments (H9C2 cells) with miR-199a-5p overexpression and angiotensin II treatment.
- Validated JunB as a direct target using dual-luciferase reporter assays and gene mutagenesis.
Main Results:
- miR-199a-5p levels significantly increased in the heart with advancing HF progression.
- Overexpression of miR-199a-5p induced apoptosis in H9C2 cells and enhanced angiotensin II-induced apoptosis.
- JunB was identified as a direct target of miR-199a-5p.
- JunB overexpression suppressed apoptosis in H9C2 cells.
Conclusions:
- miR-199a-5p is implicated in the progression of heart failure (HF).
- miR-199a-5p induces cardiomyocyte apoptosis, at least partly, by targeting and downregulating JunB.
- JunB acts as a protective factor against apoptosis in cardiomyocytes.
More Related Videos
Related Concept Videos
MicroRNAs
24.3K
MicroRNA (miRNA) are short, regulatory RNA transcribed from introns—non-coding regions of a gene—or intergenic regions—stretches of DNA present between genes. Several processing steps are required to form biologically active, mature miRNA. The initial transcript, called primary miRNA (pri-mRNA), base-pairs with itself forming a stem-loop structure. Within the nucleus, an endonuclease enzyme, called Drosha, shortens the stem-loop structure into hairpin-shaped pre-miRNA. After...
24.3K
MicroRNAs
4.0K
MicroRNA (miRNA) are short, regulatory RNA transcribed from introns (non-coding regions of a gene) or intergenic regions (stretches of DNA present between genes). Several processing steps are required to form biologically active, mature miRNA. The initial transcript, called primary miRNA (pri-mRNA), base-pairs with itself, forming a stem-loop structure. Within the nucleus, an endonuclease enzyme, called Drosha, shortens the stem-loop structure into hairpin-shaped pre-miRNA. After the pre-miRNA...
4.0K
Apoptosis
15.2K
Apoptosis is a combination of two Greek words, 'apo' and 'ptosis,' meaning separation and falling off, respectively. Hippocrates used this word to describe gangrene, which was caused due to bandaging of fractured bones. Apoptosis was distinguished from necrosis in 1970 when John Kerr reported observations of morphological changes occurring during apoptosis. During one experiment, he observed that the disruption of blood supply to the liver tissue resulted in a size...
15.2K
Targeted Cancer Therapies
9.0K
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
There are several types of targeted therapies against...
9.0K
Induced-fit Model
89.5K
Most chemical reactions in cells require enzymes—biological catalysts that speed up the reaction without being consumed or permanently changed. They reduce the activation energy needed to convert the reactants into products. Enzymes are proteins, that usually work by binding to a substrate—a reactant molecule that they act upon.
Enzymes exhibit substrate specificity, meaning that they can only bind to certain substrates. This is mainly determined by the shape and chemical...
Enzymes exhibit substrate specificity, meaning that they can only bind to certain substrates. This is mainly determined by the shape and chemical...
89.5K
Targets for Drug Action: Overview
10.5K
Drugs target macromolecules to modify ongoing cellular processes. Primary drug targets include receptors, ion channels, transporters, and enzymes.
Receptors are either membrane-spanning or intracellular proteins, which upon binding a ligand, get activated and transmit the signal downstream to elicit a response. Drugs bind receptors, either mimicking the action of endogenous ligands or blocking the receptor activity to bring about a modified response. Nearly 35% of approved drugs target the G...
Receptors are either membrane-spanning or intracellular proteins, which upon binding a ligand, get activated and transmit the signal downstream to elicit a response. Drugs bind receptors, either mimicking the action of endogenous ligands or blocking the receptor activity to bring about a modified response. Nearly 35% of approved drugs target the G...
10.5K

